Cytokine and lipid metabolome effects of low-dose acetylsalicylic acid in critically ill patients with systemic inflammation: a pilot, feasibility, multicentre, randomised, placebo-controlled trial.
Luca Cioccari, Nora Luethi, Thy Duong, Eileen Ryan, Salvatore L Cutuli, Patryck Lloyd-Donald, Glenn M Eastwood, Leah Peck, Helen Young, Suvi T Vaara, Craig J French, Neil Orford, Jyotsna Dwivedi, Yugeesh R Lankadeva, Michael Bailey, Gavin E Reid, Rinaldo Bellomo
Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine | College of Intensive Care Medicine of Australia and New Zealand | Published : 2020
OBJECTIVE: The systemic inflammatory response syndrome (SIRS) is a dysregulated response that contributes to critical illness. Adjunctive acetylsalicylic acid (ASA) treatment may offer beneficial effects by increasing the synthesis of specialised proresolving mediators (a subset of polyunsaturated fatty acid-derived lipid mediators). DESIGN: Pilot, feasibility, multicentre, double-blind, randomised, placebo-controlled trial. SETTING: Four interdisciplinary intensive care units (ICUs) in Australia. PARTICIPANTS: Critically ill patients with SIRS. INTERVENTIONS: ASA 100 mg 12-hourly or placebo, administered within 24 hours of ICU admission and continued until ICU day 7, discharge or death, whi..View full abstract